Olavide Neuron STX S.L. tiene como base una patente europea y proyectos de investigación sobre la mejora de los síntomas de enfermedades como Alzheimer, Parkinson y Corea de Huntington
Read moreCOVID-19, the disease caused by the novel coronavirus SARS-CoV-2, has infected several million people and resulted in hundreds of thousands of deaths worldwide. Although remdesivir and favipi...
Read moreWe are happy to share our latest report from the work carried out in collaboration with GlaxoSmithKline and the Drug Discovery Unit of the University of Dundee. The paper published in RSC Medicinal Ch...
Read moreLaboratories testing for COVID-19 have a new tool that enables them to skip the potentially bottlenecked RNA extraction step of the workflow and move directly to polymerase chain reaction (PCR) amplif...
Read moreThe results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo.
Read moreLa pandemia del coronavirus ha puesto de manifiesto algunas fortalezas de nuestro Sistema Nacional de Salud, pero también debilidades, y esto ha contribuido el convencimiento general de la necesidad ...
Read moreThe results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:
Read moreUna manera de entender cómo funciona un proceso celular es perturbando la actividad de un componente clave del sistema y observando como se ve afectado el proceso.
Read moreSOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020.
Read moreDespite the Covid-19 pandemic, 2020 has been a great year for ADmit Therapeutics, a spin-off from Bellvitge Biomedical Research Institute (IDIBELL, in Barcelona) born at the end of 2017 and leaded by ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today...
Read moreLAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...
Read more